260 related articles for article (PubMed ID: 24093504)
1. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
Kempsford R; Allen A; Kelly K; Saggu P; Crim C
Br J Clin Pharmacol; 2014 Mar; 77(3):466-79. PubMed ID: 24093504
[TBL] [Abstract][Full Text] [Related]
2. The pharmacodynamics, pharmacokinetics, safety and tolerability of inhaled fluticasone furoate and vilanterol administered alone or simultaneously as fluticasone furoate/vilanterol.
Kempsford R; Allen A; Bareille P; Hamilton M; Cheesbrough A
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):2-11. PubMed ID: 27127998
[TBL] [Abstract][Full Text] [Related]
3. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
4. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
[TBL] [Abstract][Full Text] [Related]
6. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
[TBL] [Abstract][Full Text] [Related]
7. Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.
Allen A; Schenkenberger I; Trivedi R; Cole J; Hicks W; Gul N; Jacques L
Clin Respir J; 2013 Oct; 7(4):397-406. PubMed ID: 23578031
[TBL] [Abstract][Full Text] [Related]
8. The safety, pharmacokinetics and pharmacodynamics of a combination of fluticasone furoate and vilanterol in healthy Japanese subjects.
Nakahara N; Wakamatsu A; Kempsford R; Allen A; Yamada M; Nohda S; Hirama T
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):660-71. PubMed ID: 23735179
[TBL] [Abstract][Full Text] [Related]
9. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
Martinez FJ; Boscia J; Feldman G; Scott-Wilson C; Kilbride S; Fabbri L; Crim C; Calverley PM
Respir Med; 2013 Apr; 107(4):550-9. PubMed ID: 23332861
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
Bhatt SP; Dransfield MT; Cockcroft JR; Wang-Jairaj J; Midwinter DA; Rubin DB; Scott-Wilson CA; Crim C
Int J Chron Obstruct Pulmon Dis; 2017; 12():351-365. PubMed ID: 28176907
[TBL] [Abstract][Full Text] [Related]
11. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.
Kempsford R; Allen A; Bal J; Rubin D; Tombs L
Br J Clin Pharmacol; 2013 Jun; 75(6):1478-87. PubMed ID: 23116485
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
[TBL] [Abstract][Full Text] [Related]
13. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
Matera MG; Capuano A; Cazzola M
Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers.
Brealey N; Gupta A; Renaux J; Mehta R; Allen A; Henderson A
Int J Clin Pharmacol Ther; 2015 Sep; 53(9):753-64. PubMed ID: 26227101
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.
Busse WW; O'Byrne PM; Bleecker ER; Lötvall J; Woodcock A; Andersen L; Hicks W; Crawford J; Jacques L; Apoux L; Bateman ED
Thorax; 2013 Jun; 68(6):513-20. PubMed ID: 23440247
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease.
Siederer S; Allen A; Yang S
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):743-758. PubMed ID: 26474864
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety evaluation of once-daily fluticasone furoate/vilanterol in Asian patients with asthma uncontrolled on a low- to mid-strength inhaled corticosteroid or low-dose inhaled corticosteroid/long-acting beta2-agonist.
Lin J; Tang H; Chen P; Wang H; Kim MK; Crawford J; Jacques L; Stone S
Allergy Asthma Proc; 2016 Jul; 37(4):302-10. PubMed ID: 27401316
[TBL] [Abstract][Full Text] [Related]
18. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.
Kerwin EM; Scott-Wilson C; Sanford L; Rennard S; Agusti A; Barnes N; Crim C
Respir Med; 2013 Apr; 107(4):560-9. PubMed ID: 23352226
[TBL] [Abstract][Full Text] [Related]
19. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
Medley H; Orozco S; Allen A
Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
